Serina Therapeutics, Inc. (SER)
| Market Cap | 41.69M -24.1% |
| Revenue (ttm) | 130,000 +154.9% |
| Net Income | -21.56M |
| EPS | -2.00 |
| Shares Out | 15.00M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 118,072 |
| Open | 2.690 |
| Previous Close | 2.670 |
| Day's Range | 2.680 - 2.860 |
| 52-Week Range | 1.220 - 7.920 |
| Beta | -0.00 |
| Analysts | Strong Buy |
| Price Target | 9.50 (+241.73%) |
| Earnings Date | Aug 13, 2026 |
About SER
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson’s disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson’s and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it ... [Read more]
Financial Performance
In 2025, Serina Therapeutics's revenue was $130,000, an increase of 132.14% compared to the previous year's $56,000. Losses were -$19.44 million, 74.5% more than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for SER stock is "Strong Buy." The 12-month stock price target is $9.5, which is an increase of 241.73% from the latest price.
News
Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
HUNTSVILLE, Ala., July 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Pl...
Serina Therapeutics completes enrollment and dosing in Parkinson’s trial
Serina Therapeutics (SER) completed enrollment and dosing in Cohort 1 of its ongoing Phase 1b registrational clinical trial evaluating SER-252 in patients with advanced Parkinson’s disease. All eight ...
Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson's Disease
- All eight patients enrolled and dosed in Cohort 1 ahead of previously disclosed guidance of the end of the third quarter of 2026 - - Independent Safety Monitoring Committee to review Cohort 1 safety...
Serina Therapeutics appoints Trevi Therapeutics CCO Farrell Simon to board
Serina Therapeutics (SER) announced the appointment of Farrell Simon to its board of directors, effective immediately. Simon will also serve on the board’s audit and compensation committees. He curren...
Serina Therapeutics Appoints Farrell Simon to its Board of Directors
HUNTSVILLE, Ala., July 22, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company advancing its proprietary POZ Pla...
Serina completes sentinel dosing in Cohort 1 of Phase 1b trial of SER-252
Serina Therapeutics (SER) announced the completion of sentinel dosing in Cohort 1 of its ongoing Phase 1b registrational clinical trial evaluating SER-252 in patients with advanced Parkinson’s disease...
Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease
HUNTSVILLE, Ala., July 09, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Pl...
Serina Therapeutics initiated with a Buy at BTIG
BTIG analyst Thomas Shrader initiated coverage of Serina Therapeutics (SER) with a Buy rating and $8 price target Serina is a clinical stage biotechnology company developing therapeutics designed to e...
Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program
HUNTSVILLE, Ala., June 30, 2026 (GLOBE NEWSWIRE) -- Gannet BioChem , a leading life sciences manufacturing company, today announced a development partnership with Serina Therapeutics, Inc. (NYSE Ameri...
Serina Therapeutics Transcript: AGM 2026
The meeting covered eight proposals, all of which were approved, including director elections, share increase, incentive plan amendment, and auditor ratification. No questions were raised by stockholders, and final voting results will be filed with the SEC.
Serina Therapeutics files to sell 16.45M shares of common stock for holders
16:01 EDT Serina Therapeutics (SER) files to sell 16.45M shares of common stock for holders
Serina Therapeutics Registration statement: Registration filing
Serina Therapeutics filed a registration statement on May 22, 2026, providing details about a securities offering with the SEC.
Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Phase 1b Registrational Clinical Study of SER-252 Underway in Advanced Parkinson's Disease; TFL data from the SAD study arm targeted for first half of 2027 -
Serina Therapeutics Quarterly report: Q1 2026
Serina Therapeutics has published its Q1 2026 quarterly earnings report on May 14, 2026.
Serina Therapeutics Earnings release: Q1 2026
Serina Therapeutics released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Serina Therapeutics Proxy statement: Proxy filing
Serina Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Serina Therapeutics Proxy statement: Proxy filing
Serina Therapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Serina Therapeutics Proxy statement: Proxy filing
Serina Therapeutics filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit
– Novel lipid nanoparticles entirely built on the POZ Platform that overcome the PEG immunogenicity dilemma – Design & synthesis of novel ionizable POZ lipids to replace current ionizable lipids for t...
Serina Therapeutics announces NYSE acceptance of plan to regain compliance
Serina Therapeutics (SER) reported that the NYSE has accepted the company’s business plan to regain compliance with the continued listing standards set forth in Section 1003 of the NYSE American…
Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan
HUNTSVILLE, April 02, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platfor...
Serina Therapeutics Annual report: Q4 2025
Serina Therapeutics has published its Q4 2025 annual report on March 25, 2026.
Serina Therapeutics Earnings release: Q4 2025
Serina Therapeutics released its Q4 2025 earnings on March 25, 2026, summarizing the period's financial results.
Serina Therapeutics Transcript: 38th Annual Roth Conference
The POZ platform enables improved delivery of small molecules, with lead program SER-252 in advanced Parkinson's showing promise for best-in-class therapy and a $1.7–$2.5 billion market opportunity. Additional programs target tardive dyskinesia and an undisclosed CNS indication, with a focus on accelerated regulatory pathways and potential partnerships.
Serina Therapeutics to Present at the 38th Annual Roth Conference
HUNTSVILLE, AL, March 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optim...